跳至主要内容
临床试验/RBR-33wrhzd
RBR-33wrhzd进行中(未招募)Unknown

Evaluation of use of Probiotics in prevention of Irinotecan and/or Fluoropyrimidines induced Diarrhea in patients with gastrointestinal tract Cancer

niversidade Federal de São Paulo0 个研究点开始时间: 2024年4月22日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18Y 至 85Y(—)

入选标准

  • Age between 18 and 85 years old; Diagnosis of primary gastrointestinal tract tumor (esophagus, stomach, pancreas, colon and rectum); Planning to start chemotherapy treatment with chemotherapy protocols containning irinotecan and/or fluoropyrimidines; Performance scale according to the Eastern Cooperative Oncology Group (ECOG) between 0-2

排除标准

  • Severe systemic diseases including heart disease, coagulopathies, renal and hepatic dysfunction; History of severe diarrhea during previous treatment; Use of probiotics, prebiotics up to 2 months before recruitment; Pregnant and lactating women; Incapable patient; Not signed the Informed Consent Form

研究者

发起方
niversidade Federal de São Paulo

相似试验